RESEARCH TRIANGLE PARK – Metabolon,  a developer of biomarker technology based in RTP, has appointed Dr. Karl Bradshaw, as vice president of Biopharma Strategy and Partnering.

Dr. Bradshaw will be responsible for delivering biopharma partnerships that leverage Metabolon’s “unique technical capabilities and biological insights to generate significant mutual value for both parties.”

“It is apparent to me that Metabolon is a clear world leader in metabolomics and is an essential component of the multi-omics revolution,” he said in a statement.  “I am thrilled to help lead the company’s journey to accelerate research and product development success across the biopharma industry by revealing previously unseen biological insights.”

Bradshaw joins Metabolon from AstraZeneca, where he most recently served as senior director of Corporate Strategy and Development. Bradshaw held several roles during his six-year tenure at AstraZeneca, including head of Competitive Intelligence for infection, neuroscience and GI, and business D\development director for AstraZeneca’s Antibiotics Business Unit.

Prior to joining AstraZeneca, Bradshaw worked for seven years as Vice President of Equity Research at Morgan Stanley, where he gained extensive experience in financial analysis, modelling and valuation of biotech and MedTech companies, as well as an excellent understanding of global healthcare sector trends and underlying market demographics.

Heearned his undergraduate degree in biological sciences from Birmingham University and a doctorate in neuroscience from University College London. He conducted postdoctoral work at the National Institute for Medical Research, later completing an Master of Philosophy in Bioscience Enterprise from Cambridge University.

Founded in 2000, th company specializes in a technology called metabolomics, which is the large-scale study of small molecules, commonly known as metabolites, within cells, biofluids, tissues or organisms.

Metabolon’s proprietary Precision Metabolomics technology provides researchers with the ability to profile a subject’s or patient’s metabolome for applications in precision medicine and to advance understanding of the metabolic basis of disease, disease progression and treatment mechanisms.

The company is currently teaming up with three Canadian research groups to discover humans’ frailty biomarkers, determine the severity of frailty and what can be done to help avoid the condition.